Akari Therapeutics Plc (AKTX)

5.80 +0.68 (+13.28%) USD  |  NASDAQ  |  Apr 17, 16:00
5.13 -0.67 (-11.55%) Pre-Market: 08:28
More

Akari Therapeutics SG&A Expense (Quarterly) : 2.138M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for AKTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
DBV Technologies SA 12.79M
Cellectis SA 4.798M
Biodexa Pharmaceuticals Plc --
Mereo BioPharma Group Plc 4.191M
Bicycle Therapeutics Plc 20.86M